<?xml version="1.0" encoding="UTF-8"?>
<p>The PD-1 pathway may also become upregulated due to longer disease duration and following anti-cancer treatment in relapsed malignancies[
 <xref rid="pone.0204870.ref013" ref-type="bibr">13</xref>, 
 <xref rid="pone.0204870.ref014" ref-type="bibr">14</xref>]. Increased proportions of PD-L1+ tumor cells in non-small cell lung cancer (NSCLC)[
 <xref rid="pone.0204870.ref015" ref-type="bibr">15</xref>], and PD-1+ lymphocytes in multiple myeloma[
 <xref rid="pone.0204870.ref016" ref-type="bibr">16</xref>] were observed at relapse compared to primary diagnosis. It is unclear to what extent the PD-1 pathway changes in cHL when primary and relapse samples are compared.
</p>
